(Q35609554)

9 August 2017

1 reference

title

Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management (English)

1 reference

9 August 2017

1 reference

Charles Catton

1

1 reference

9 August 2017

Michael Milosevic

2

1 reference

9 August 2017

Padraig Warde

3

1 reference

9 August 2017

Andrew Bayley

4

1 reference

9 August 2017

Juanita Crook

5

1 reference

9 August 2017

Robert Bristow

6

1 reference

9 August 2017

Mary Gospodarowicz

7

1 reference

9 August 2017

1 November 2003

1 reference

Urologic Clinics of North America

9 August 2017

1 reference

9 August 2017

30

1 reference

9 August 2017

4

1 reference

9 August 2017

751-763

1 reference

PSAdynia and other PSA-related syndromes: a new epidemic--a case history and taxonomy.

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

The impact of irregularly rising prostate-specific antigen and “impending failure” on the apparent outcome of localized prostate cancer following radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Definitions of biochemical failure in prostate cancer following radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Patterns and fate of PSA bouncing following 3D-CRT

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Value of sextant biopsies in the assessment of local cure following external beam radiotherapy of prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356)

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Positron emission tomography in prostate and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Radical prostatectomy after definitive radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

The role of radical surgery in the management of radiation recurrent and large volume prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Salvage Radical Prostatectomy for Radiorecurrent Adenocarcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Image-guided prostate cryosurgery: state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Salvage brachytherapy for localized prostate cancer after radiotherapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Permanent brachytherapy as salvage treatment for recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Intermittent androgen suppression in the management of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

Osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900051-X

7 January 2021

10.1016/S0094-0143(03)00051-X

Identifiers

DOI

1 reference

9 August 2017

1 reference